|1.||Watson, Y: 1 article (02/2005)|
|2.||Rolfe, L: 1 article (02/2005)|
|3.||Mullamitha, S: 1 article (02/2005)|
|4.||Valle, J W: 1 article (02/2005)|
|5.||Broughton, L: 1 article (02/2005)|
|6.||Jayson, G C: 1 article (02/2005)|
|7.||Roberts, C: 1 article (02/2005)|
|8.||Issa, B: 1 article (02/2005)|
|9.||Zinkewich-Péotti, K: 1 article (02/2005)|
|10.||Buckley, D L: 1 article (02/2005)|
02/10/2005 - "The purpose of this study was to determine whether changes in tumor vascular parameters could be detected in humans, and to assess whether CDP860 would be likely to increase the uptake of a concurrently administered small molecule in future studies. "
02/10/2005 - "However, in cancer patients, further exploration of the dosing regimen of CDP860 is required to dissociate adverse effects from beneficial effects. "
02/10/2005 - "In some patients, the ratio of vascular volume to total tumor volume increased significantly (P < .001) within 24 hours following CDP860 administration, an effect suggestive of recruitment of previously non-functioning vessels. "
02/10/2005 - "Blockade of platelet-derived growth factor receptor-beta by CDP860, a humanized, PEGylated di-Fab', leads to fluid accumulation and is associated with increased tumor vascularized volume."
|3.||Colorectal Neoplasms (Colorectal Cancer)
|1.||Platelet-Derived Growth Factor Receptors (Platelet-Derived Growth Factor Receptor)